Kyverna Therapeutics (NASDAQ:KYTX) Upgraded by Wall Street Zen to Hold Rating

Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Several other equities research analysts also recently commented on the stock. HC Wainwright lifted their target price on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company increased their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Stock Down 1.5%

Shares of KYTX stock opened at $8.32 on Friday. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $13.67. The stock’s fifty day simple moving average is $7.91 and its 200 day simple moving average is $5.78. The firm has a market capitalization of $364.42 million, a P/E ratio of -2.23 and a beta of 3.45.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.12. As a group, equities research analysts expect that Kyverna Therapeutics will post -3.29 EPS for the current fiscal year.

Insider Activity at Kyverna Therapeutics

In other news, Director Beth C. Seidenberg purchased 133,333 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $7.50 per share, with a total value of $999,997.50. Following the completion of the transaction, the director owned 869,317 shares of the company’s stock, valued at $6,519,877.50. The trade was a 18.12% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of the stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $7.50 per share, with a total value of $999,997.50. Following the completion of the transaction, the insider owned 869,317 shares in the company, valued at approximately $6,519,877.50. This represents a 18.12% increase in their position. The SEC filing for this purchase provides additional information. 22.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC boosted its holdings in Kyverna Therapeutics by 25.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock worth $59,000 after acquiring an additional 3,847 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Kyverna Therapeutics during the third quarter worth about $28,000. Rhumbline Advisers grew its position in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Bank of America Corp DE increased its stake in Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after buying an additional 6,400 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in Kyverna Therapeutics by 22.2% in the 2nd quarter. Federated Hermes Inc. now owns 44,000 shares of the company’s stock valued at $135,000 after buying an additional 8,000 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.